Company Overview and News
On Jun 15, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from continued momentum in new business generation and expanding geographies. The stock carries a Zacks Rank #2 (Buy).
HD SYK HAE ISRG ABMD
Brightree, the wholly owned subsidiary of ResMed Inc. (RMD - Free Report) , recently entered into a strategic partnership with athenahealth (ATHN - Free Report) , a leading provider of network-enabled services for hospital and ambulatory clients.
HD RMD SYK RSMDF RMD ABMD ATHN
Surmodics, Inc (SRDX - Free Report) is currently a top performer in the MedTech space. Improved price performance and strong fundamentals instill investors’ optimism in the stock. Therefore, its time you take advantage of the stock price appreciation.
VAR SRDX ABMD GHDX
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA
Express Scripts Holding Company (ESRX - Free Report) has underperformed the broader industry in the last three months. The company’s shares have gained 8.2% versus the industry’s rally of 8.8%.
SPG.PRJ SYK SPG ISRG CI ABMD
Medtronic PLC’s (NYSE:MDT) brain therapy business gets a boost with the recent Food and Drug Administration approval for the company’s latest Deep Brain Stimulation (DBS) Clinician Programmer and ActivaProgramming Application. This U.S. approval has come close on the heels of the European CE mark approval for the same application in March 2018.
SYK ABMD GHDX MDT
On Jun 11, we issued an updated research report on PetMedExpress, Inc. (PETS - Free Report) . The stock carries a Zacks Rank #2 (Buy). The company is striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items while also expanding the product line.
SYK CSX MGYTF ABMD GHDX
Medtronic plc’s (MDT - Free Report) brain therapy business gets a boost with the recent FDA approval for the company’s latest Deep Brain Stimulation (DBS) Clinician Programmer and ActivaProgramming Application. This U.S. approval has come close on the heels of the European CE mark approval for the same in March 2018.
SYK CSX MGYTF ABMD GHDX MDT
The Medical Instrument industry within the broader Medical universe has been gaining on R&D innovation, higher consolidation, focus on emerging market and tax abolition. The industry increased 3.6% in a month’s time, higher than the S&P 500 index’s rise of 2%.
ALGN VAR BSX SYK WYN ISRG ABMD WYND
Cardinal Health’s (CAH - Free Report) premarket approval (PMA) application for INCRAFT (INCRAFT Stent Graft System) recently received favorable recommendation from the FDA. The Circulatory System Devices Panel of the Medical Devices Advisory Committee voted 11 to 4 in favor of the system.
SYK CAH ABMD GHDX
Varian Medical (VAR - Free Report) is currently a top performer in the MedTech space. Improved price performance and strong fundamentals instill investors’ confidence in the stock.
XOM SYK ISRG ABMD
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to ABMD / ABIOMED, Inc. on message board site Silicon Investor.
|ABMD - Replacement Heart System||ABIOMED --an under valued small co.|
as of ET